Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<i>In Silico</i> Studies of the Hepatitis B Virus Polymerase: Efforts to Identify Novel Drug Binding Sites to Inhibit HBV Replication.

Missouri medicine·2026

Same author

Hepatitis B virus ribonuclease H inhibitors: Coming of age?

Antiviral research·2026

Same author

Correction to "Design, Synthesis, and Biological Evaluation of Highly Potent Boronic Acid (Boronate Ester)-Bearing Heteroaryldihydropyrimidine Derivatives as HBV Capsid Assembly Modulators".

Journal of medicinal chemistry·2025

Same author

Design, Synthesis, and Biological Evaluation of Highly Potent Boronic Acid (Boronate Ester)-Bearing Heteroaryldihydropyrimidine Derivatives as HBV Capsid Assembly Modulators.

Journal of medicinal chemistry·2025

Same author

Correction for Woodson et al., "Efficacy and <i>in vitro</i> pharmacological assessment of novel <i>N</i>-hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors".

Antimicrobial agents and chemotherapy·2025

Same author

Discovery of <i>N</i>-Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Dec 22, 2025

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

HBV replication inhibitors.

Claire Pierra Rouviere¹, Cyril B Dousson¹, John E Tavis²

¹Ai-biopharma, Medicinal Chemistry Department, Montpellier, France.

Antiviral Research

|May 8, 2020

Summary

New Hepatitis B Virus (HBV) therapies aim to inhibit viral replication. Developing improved nucleos(t)ide analogs (NAs) and targeting other viral enzymes are key strategies for future HBV cures.

Keywords:

Chronic hepatitis B Hepatitis B virus Nucleos(t)ide analogs Reverse transcriptase inhibitors Ribonuclease H inhibitors

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Dec 22, 2025

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

Hepatology
Virology
Drug Discovery

Background:

Chronic Hepatitis B Virus (HBV) infection affects over 250 million people globally, causing nearly 1 million deaths annually.
Current treatments, primarily nucleos(t)ide analogs (NAs), suppress viral DNA synthesis but do not eliminate the virus, leading to persistent infection and resistance.
Residual viral replication during NA therapy maintains the covalently closed circular DNA (cccDNA) reservoir and ongoing infection of new cells.

Purpose of the Study:

To explore novel therapeutic strategies for chronic HBV infection beyond current NA limitations.
To identify and develop next-generation HBV replication inhibitors with enhanced efficacy and safety profiles.
To investigate potential new drug targets within the complex HBV reverse transcription pathway.

Main Methods:

Focus on developing novel prodrug approaches for improved nucleos(t)ide analogs (NAs).
Preclinical development of inhibitors targeting HBV ribonuclease H, an enzyme crucial for viral replication.
Exploration of alternative targets including HBV's protein-priming mechanism and host factors supporting viral reverse transcriptase function.

Main Results:

Ongoing efforts are focused on identifying next-generation NAs with improved efficacy and safety.
Inhibitors of HBV ribonuclease H are in preclinical development.
Various other targets within the HBV reverse transcription pathway are being investigated.

Conclusions:

Improved inhibitors of HBV reverse transcription are essential for reducing viral persistence.
These inhibitors are expected to be a cornerstone of future combination therapies aimed at curing HBV infection.
Targeting viral replication mechanisms offers a promising avenue for developing curative HBV treatments.